ClinicalTrials.gg
CompletedNCT04375397iNSPIREUpdated Jun 1, 2022Results posted

Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

A Phase 2 interventional study of Ibrutinib and Placebo in CoronaVirus Induced Disease-2019 (COVID-19), sponsored by AbbVie. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
852nd of 1,321
46 · median 91
Started
2020
with 817 others
Phase 2
349 of 1,859
14 open now
Registered
279th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 852nd largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 279th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection. The main objective of this study was to evaluate if ibrutinib is safe and can reduce respiratory failure in participants with COVID-19 infection.

Read the detailed description

This was a Phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the addition of ibrutinib to supportive care in hospitalized participants who presented with COVID-19- related pulmonary distress requiring supplemental oxygen. Participants were randomized in a 1:1 ratio to receive placebo + supportive care, denoted as SOC or standard-of-care, or ibrutinib 420 mg + SOC, with randomization stratified by prescription for remdesivir.

Participants were to be treated with either placebo or ibrutinib in addition to supportive care for up to 28 days unless they met treatment discontinuation criteria and were to be followed for 58 days following start of therapy or until death, whichever occurred first. Treatment could have been stopped at the discretion of the treating physician after 14 days if the participant was clinically stable and had been off supplemental oxygen for > 48 hours.

03

Conditions studied

  • CoronaVirus Induced Disease-2019 (COVID-19)

Keywords

  • CoronaVirus Induced Disease-2019
  • COVID-19
  • Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
  • Pulmonary Injury
  • Ibrutinib
  • Imbruvica
  • Respiratory failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Requires hospitalization for COVID-19 infection
  • Has Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by reverse transcription polymerase chain reaction (RT-PCR) test before study entry
  • Requires supplemental oxygen for pulmonary distress related to COVID-19 infection, and has been on supplemental oxygen for no more than 5 days, and on breathing room air have oxygen saturation levels of 94% or less
  • Has radiographic evidence of pulmonary infiltrates
  • Females of (FCBP) must use 1 reliable form of or have complete abstinence from heterosexual intercourse during the following time periods related to this study: while participating in the study; and for at least 1 month after discontinuation of study drug. FCBP must be referred to a qualified provider of contraceptive methods if needed. FCBP must have a negative serum pregnancy test as of screening.
  • Men must agree to use a latex condom during treatment and for up to 3 months after the last dose of ibrutinib during sexual contact with a FCBP.
  • Adequate hematologic, hepatic and renal function as described in the protocol
  • Must be within 10 days of confirmed diagnosis of COVID-19

Exclusion criteria

Exclusion Criteria:

  • Respiratory failure at time of screening as defined per protocol with any of these following therapies:

    • Endotracheal intubation and mechanical ventilation
    • Extracorporeal membrane oxygenation (ECMO)
    • High flow nasal cannula oxygen at flow rates ≥ 30 L/min and fraction of delivered oxygen ≥ 0.5
    • Non-invasive positive pressure ventilation
  • Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction
  • On a Bruton's tyrosine kinase (BTK)-inhibitor, anti-interleukin 6 (IL6), anti-interleukin 6R (IL6R), or Janus kinase inhibitor (JAKi)
  • Has received rituximab within 180 days from study entry.
  • Known bleeding disorders
  • Major surgery within 4 weeks of study entry
  • Participants in whom surgery is anticipated to be necessary within 72 hours
  • History of stroke or bleeding around or within brain within 6 months prior to enrollment
  • Known history of (HIV) or active with virus (HCV) or virus (HBV)
  • Currently active, cardiovascular disease
  • Asymptomatic arrythmias and or history of \< 40% on an echo
  • Participants receiving a strong cytochrome P450 (CYP) 3A4 inhibitor with the exception of those receiving anti-fungal therapy/prophylaxis
  • Chronic liver disease and hepatic impairment meeting class C
  • Female participants who are pregnant, or breastfeeding, or planning to become pregnant while enrolled in this study or within 1 month of last dose of study drug. Male participants who plan to father a child while enrolled in this study or within 3 months after the last dose of study drug.
  • Unwilling or unable to participate in all required study evaluations and procedures
  • Vaccinated with a live, attenuated vaccine within 4 weeks
  • Uncontrolled high blood pressure
  • On therapeutic anticoagulation at baseline
  • Participants with cancer, history of interstitial lung disease, and/or history of as defined in the protocol
  • Co-enrolled in another interventional trial
  • (AST) or alanine aminotransferase (ALT) ≥ 3.0 × , and total > 2.0 × ULN
  • (INR) ≥ 1.5 × ULN attributable to coagulation disorders
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Ibrutinib 420 mg + SOC

    420 mg ibrutinib administered once daily as three hard gelatin capsules (140 mg each) with approximately 240 mL of water for up to 28 days and supportive care (standard-of-care, SOC)

    Drug: Ibrutinib

  • Placebo comparator
    Placebo + SOC

    Three hard gelatin placebo capsules administered once daily with approximately 240 mL of water for up to 28 days and supportive care (standard-of-care, SOC)

    Drug: Placebo

Interventions

  • Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.

    Also known as: Imbruvica

  • DrugPlacebo

    Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Alive and Without Respiratory Failure Through Day 28

    Respiratory failure is defined as a clinical diagnosis of respiratory failure and initiation of one of the following therapies: endotracheal intubation and mechanical ventilation; OR extracorporeal membrane oxygenation; OR high-flow nasal cannula oxygen delivery (i.e., reinforced nasal cannula delivering heated, humidified oxygen with fraction of delivered oxygen ≥ 0.5 and flow rates of ≥ 30 L/min); OR non-invasive positive pressure ventilation; OR clinical diagnosis of respiratory failure with initiation of none of these measures only when clinical decision-making is driven solely by resource limitation.

    Time frame: Through Day 28

Secondary outcomes

  1. Change in the World Health Organization (WHO)-8 Ordinal Scale From Baseline at Study Day 14

    The WHO-8 is an ordinal scale for clinical improvement with scores ranging from 0 to 8, where a lower score indicates better clinical status. A score of 0 represents uninfected; 1 (ambulatory, no limitation of activities); 2 (ambulatory, limitation of activities); 3 (hospitalized with mild disease, no oxygen therapy); 4 (hospitalized with mild disease, oxygen by mask or nasal prongs); 5 (hospitalized with severe disease, non-invasive ventilation or high-flow oxygen); 6 (hospitalized with severe disease, intubation and mechanical ventilation); 7 (hospitalized with severe disease, ventilation and additional organ support \[pressors, renal replacement therapy, extracorporeal membrane oxygenation\]); and 8 (death). Negative values indicate improvement from baseline.

    Time frame: At Day 14

  2. Median Reduction in Days Spent on Supplemental Oxygen

    Days spent on supplemental oxygen was set as the date of the participant being off of supplemental oxygen minus the date of initiation of supplemental oxygen + 1 day. If a participant received more than 1 period of supplemental oxygen therapy during the study or switched from supplemental oxygen to a more intensive therapy, then the days spent on supplemental oxygen were to be calculated as the sum of all the periods where the participant was on supplemental oxygen or a more intensive therapy through Day 28. If the date of the first initiation of supplemental oxygen was before Baseline Day 1, then the days spent on supplemental oxygen were to be calculated from Baseline Day 1 to the date of the participant being off the supplemental oxygen. Time on supplemental oxygen was to be imputed to the maximum number of days on study drug (28) for all points following the death of a participant.

    Time frame: Up to Day 28

  3. All-Cause Mortality at Study Days 7, 14, 21, and 28

    The percentage of participants with mortality from any cause was recorded.

    Time frame: At Study Days 7, 14, 21, and 28

  4. Percentage of Participants Experiencing Respiratory Failure or Death on Study Days 7, 14, 21, and 28

    Respiratory failure is defined as a clinical diagnosis of respiratory failure and initiation of one of the following therapies: endotracheal intubation and mechanical ventilation; OR extracorporeal membrane oxygenation; OR high-flow nasal cannula oxygen delivery (i.e., reinforced nasal cannula delivering heated, humidified oxygen with fraction of delivered oxygen ≥ 0.5 and flow rates of ≥ 30 L/min), OR non-invasive positive pressure ventilation; OR clinical diagnosis of respiratory failure with initiation of none of these measures only when clinical decision-making is driven solely by resource limitation.

    Time frame: At Study Days 7, 14, 21, and 28

  5. Mechanical Ventilation-Free Survival

    Mechanical ventilation-free survival is defined as the number of days from Baseline Day 1 to the date when a participant initiated mechanical ventilation or died, whichever occurred first, during the 28 days post baseline. If the specified event did not occur by Day 28, participants were to be censored. Specifically, a participant without any post-baseline assessment record was to be censored at Baseline Day 1, a participant who prematurely discontinued from study without a record of death or start of mechanical ventilation was to be censored at the earlier timepoint of the date of study discontinuation or Day 28, an ongoing participant in the study without a record of death or start of mechanical ventilation was to be censored at the earlier timepoint of the date of the last evidence that the participant is not on mechanical ventilation or Day 28.

    Time frame: Up to Day 28

  6. Days on Mechanical Ventilation

    Days spent on mechanical ventilation was defined as the date of the participant being off mechanical ventilation - date of initiation of mechanical ventilation + 1 day. If a participant received more than 1 period of mechanical ventilation during the study or switched from mechanical ventilation to a more intensive therapy, then the days spent on mechanical ventilation were to be calculated as the sum of all the periods where the participant is on mechanical ventilation or a more intensive therapy through Day 28.

    Time frame: Up to Day 28

  7. Median Duration of Hospitalization

    Median duration of hospitalization is defined as the hospitalization discharge date - hospitalization admission date + 1 day. If a participant was hospitalized more than once during the study then the hospitalization time was to be calculated as the sum of all the periods when the participant was hospitalized through Day 28.

    Time frame: Up to Day 28

  8. Time to Discharge From Hospital

    Time to discharge from hospital is defined as the number of days from Baseline Day 1 to the date of the last evidence that a participant is last discharged from hospital, during the 28 days post baseline. If the specified event did not occur by Day 28, participants were censored. Specifically, a participant without any postbaseline assessment record was to be censored at Baseline Day 1, a participant who died was to have time to discharge from hospital censored at Day 28, a participant who prematurely discontinued from study without a record of hospitalization discharge was to be censored at the earlier timepoint of the date of study discontinuation or Day 28, an on-going participant in the study without a record of hospitalization discharge was to be censored at the earlier timepoint of the date of the last evidence that the participant is hospitalized or Day 28.

    Time frame: Up to Day 28

  9. Partial Pressure of Oxygen in Arterial Blood (PaO2) to Fraction of Inspired Oxygen (FiO2) Ratio

    The PaO2/FiO2 ratio is the ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2). A PaO2/FiO2 ratio of 300 to 200 is mild, 200 to 100 moderate, and \<100 is severe Adult Respiratory Distress Syndrome (ARDS).

    Time frame: At Study Days 7, 14, 21, and 28

  10. Oxygenation Index

    The oxygenation index is used to assess the intensity of ventilatory support required to maintain oxygenation. An index of 0 to \< 25 is predictive of a good outcome; 25 to \<40 indicates a chance of death \>40%; and an index of 40 to 1000 warrants consideration of extracorporeal membrane oxygenation (ECMO).

    Time frame: At Study Days 7, 14, 21, and 28

  11. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events (TEAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: From first dose of study drug until 30 days following last dose of study drug (up to 70 days)

07

Results

Posted Jun 1, 2022

Participant flow

Participant flow — Overall Study
MilestoneIbrutinib 420 mg + SOCPlacebo + SOC
Started2224
Completed1318
Not completed96
Withdrew: Death11
Withdrew: Withdrew consent20
Withdrew: Lost to follow-up64
Withdrew: Other, not specified01

Outcome measures

PrimaryPercentage of Participants Alive and Without Respiratory Failure Through Day 28

Respiratory failure is defined as a clinical diagnosis of respiratory failure and initiation of one of the following therapies: endotracheal intubation and mechanical ventilation; OR extracorporeal membrane oxygenation; OR high-flow nasal cannula oxygen delivery (i.e., reinforced nasal cannula delivering heated, humidified oxygen with fraction of delivered oxygen ≥ 0.5 and flow rates of ≥ 30 L/min); OR non-invasive positive pressure ventilation; OR clinical diagnosis of respiratory failure with initiation of none of these measures only when clinical decision-making is driven solely by resource limitation.

Time frame:
Through Day 28
Reported as:
Number · percentage of participants
Percentage of Participants Alive and Without Respiratory Failure Through Day 28
percentage of participantsIbrutinib 420 mg + SOCPlacebo + SOC
Percentage of Participants Alive and Without Respiratory Failure Through Day 2886.4 (74.4 to 93.2)79.2 (66.9 to 87.7)
Statistical analysis
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen method · p = =0.599 · Adjusted risk difference (%): 5.8 · 80% CI -9.2 to 20.4Ibrutinib 420 mg + SOC - Placebo + SOC Miettinen-Nurminen (MN) CI for the adjusted risk difference across strata
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen method · p = =0.599 · Adjusted risk difference (%): 5.8 · 95% CI -18.1 to 28.7Ibrutinib 420 mg + SOC - Placebo + SOC Miettinen-Nurminen (MN) CI for the adjusted risk difference across strata
SecondaryChange in the World Health Organization (WHO)-8 Ordinal Scale From Baseline at Study Day 14

The WHO-8 is an ordinal scale for clinical improvement with scores ranging from 0 to 8, where a lower score indicates better clinical status. A score of 0 represents uninfected; 1 (ambulatory, no limitation of activities); 2 (ambulatory, limitation of activities); 3 (hospitalized with mild disease, no oxygen therapy); 4 (hospitalized with mild disease, oxygen by mask or nasal prongs); 5 (hospitalized with severe disease, non-invasive ventilation or high-flow oxygen); 6 (hospitalized with severe disease, intubation and mechanical ventilation); 7 (hospitalized with severe disease, ventilation and additional organ support \[pressors, renal replacement therapy, extracorporeal membrane oxygenation\]); and 8 (death). Negative values indicate improvement from baseline.

Time frame:
At Day 14
Reported as:
Count of participants · Participants
Change in the World Health Organization (WHO)-8 Ordinal Scale From Baseline at Study Day 14
ParticipantsIbrutinib 420 mg + SOCPlacebo + SOC
-4 points23
-3 points129
-2 points57
-1 point02
0 points11
1 point11
3 points11
Statistical analysis
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Multinomial Logistic Regression · p = =0.886 · Odds ratio (or): 1.17 · 95% CI 0.13 to 10.44
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Multinomial Logistic Regression · p = =0.705 · Odds ratio (or): 0.64 · 95% CI 0.06 to 6.43
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Multinomial Logistic Regression · p = =0.996 · Odds ratio (or): 0.00
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Multinomial Logistic Regression · p = =0.969 · Odds ratio (or): 1.07 · 95% CI 0.04 to 32.18
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Multinomial Logistic Regression · p = =0.969 · Odds ratio (or): 1.07 · 95% CI 0.04 to 32.18
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Multinomial Logistic Regression · p = =0.969 · Odds ratio (or): 1.07 · 95% CI 0.04 to 32.18
SecondaryMedian Reduction in Days Spent on Supplemental Oxygen

Days spent on supplemental oxygen was set as the date of the participant being off of supplemental oxygen minus the date of initiation of supplemental oxygen + 1 day. If a participant received more than 1 period of supplemental oxygen therapy during the study or switched from supplemental oxygen to a more intensive therapy, then the days spent on supplemental oxygen were to be calculated as the sum of all the periods where the participant was on supplemental oxygen or a more intensive therapy through Day 28. If the date of the first initiation of supplemental oxygen was before Baseline Day 1, then the days spent on supplemental oxygen were to be calculated from Baseline Day 1 to the date of the participant being off the supplemental oxygen. Time on supplemental oxygen was to be imputed to the maximum number of days on study drug (28) for all points following the death of a participant.

Time frame:
Up to Day 28
Reported as:
Median · days
Median Reduction in Days Spent on Supplemental Oxygen
daysIbrutinib 420 mg + SOCPlacebo + SOC
Median Reduction in Days Spent on Supplemental Oxygen5.0 (1 to 28)6.5 (1 to 21)
Statistical analysis
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Van Elteren's test · p = =0.801 · Difference in medians: -1.5Ibrutinib 420 mg + SOC - Placebo + SOC
SecondaryAll-Cause Mortality at Study Days 7, 14, 21, and 28

The percentage of participants with mortality from any cause was recorded.

Time frame:
At Study Days 7, 14, 21, and 28
Reported as:
Number · percentage of participants
All-Cause Mortality at Study Days 7, 14, 21, and 28
percentage of participantsIbrutinib 420 mg + SOCPlacebo + SOC
Day 70 (0.0 to 6.9)0 (0.0 to 6.4)
Day 140 (0.0 to 6.9)0 (0.0 to 6.4)
Day 214.5 (1.4 to 14.0)0 (0.0 to 6.4)
Day 284.5 (1.4 to 14.0)0 (0.0 to 6.4)
Statistical analysis
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =1.000 · Mortality rate difference: 0.0 · 80% CI -6.7 to 7.3
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =1.000 · Mortality rate difference: 0.0 · 95% CI -14.4 to 15.5
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =1.000 · Mortality rate difference: 0.0 · 80% CI -6.7 to 7.3
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =1.000 · Mortality rate difference: 0.0 · 95% CI -14.4 to 15.5
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =0.267 · Mortality rate difference: 4.8 · 80% CI -1.7 to 14.8
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =0.267 · Mortality rate difference: 4.8 · 95% CI -9.6 to 22.8
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =0.267 · Mortality rate difference: 4.8 · 80% CI -1.7 to 14.8
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =0.267 · Mortality rate difference: 4.8 · 95% CI -9.6 to 22.8
SecondaryPercentage of Participants Experiencing Respiratory Failure or Death on Study Days 7, 14, 21, and 28

Respiratory failure is defined as a clinical diagnosis of respiratory failure and initiation of one of the following therapies: endotracheal intubation and mechanical ventilation; OR extracorporeal membrane oxygenation; OR high-flow nasal cannula oxygen delivery (i.e., reinforced nasal cannula delivering heated, humidified oxygen with fraction of delivered oxygen ≥ 0.5 and flow rates of ≥ 30 L/min), OR non-invasive positive pressure ventilation; OR clinical diagnosis of respiratory failure with initiation of none of these measures only when clinical decision-making is driven solely by resource limitation.

Time frame:
At Study Days 7, 14, 21, and 28
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Respiratory Failure or Death on Study Days 7, 14, 21, and 28
percentage of participantsIbrutinib 420 mg + SOCPlacebo + SOC
Day 79.1 (3.8 to 20.0)20.8 (12.3 to 33.1)
Day 149.1 (3.8 to 20.0)20.8 (12.3 to 33.1)
Day 2113.6 (6.8 to 25.6)20.8 (12.3 to 33.1)
Day 2813.6 (6.8 to 25.6)20.8 (12.3 to 33.1)
Statistical analysis
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =0.314 · Adjusted risk difference (%): -10.7 · 80% CI -24.8 to 3.3
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =0.314 · Adjusted risk difference (%): -10.7 · 95% CI -32.8 to 12.0
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =0.314 · Adjusted risk difference (%): -10.7 · 80% CI -24.8 to 3.3
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =0.314 · Adjusted risk difference (%): -10.7 · 95% CI -32.8 to 12.0
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =0.599 · Adjusted risk difference (%): -5.8 · 80% CI -20.4 to 9.2
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =0.599 · Adjusted risk difference (%): -5.8 · 95% CI -28.7 to 18.1
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =0.599 · Adjusted risk difference (%): -5.8 · 80% CI -20.4 to 9.2
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Miettinen-Nurminen · p = =0.599 · Adjusted risk difference (%): -5.8 · 95% CI -28.7 to 18.1
SecondaryMechanical Ventilation-Free Survival

Mechanical ventilation-free survival is defined as the number of days from Baseline Day 1 to the date when a participant initiated mechanical ventilation or died, whichever occurred first, during the 28 days post baseline. If the specified event did not occur by Day 28, participants were to be censored. Specifically, a participant without any post-baseline assessment record was to be censored at Baseline Day 1, a participant who prematurely discontinued from study without a record of death or start of mechanical ventilation was to be censored at the earlier timepoint of the date of study discontinuation or Day 28, an ongoing participant in the study without a record of death or start of mechanical ventilation was to be censored at the earlier timepoint of the date of the last evidence that the participant is not on mechanical ventilation or Day 28.

Time frame:
Up to Day 28
Reported as:
Median · days
Mechanical Ventilation-Free Survival
daysIbrutinib 420 mg + SOCPlacebo + SOC
Mechanical Ventilation-Free SurvivalNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Log Rank · p = =0.851
SecondaryDays on Mechanical Ventilation

Days spent on mechanical ventilation was defined as the date of the participant being off mechanical ventilation - date of initiation of mechanical ventilation + 1 day. If a participant received more than 1 period of mechanical ventilation during the study or switched from mechanical ventilation to a more intensive therapy, then the days spent on mechanical ventilation were to be calculated as the sum of all the periods where the participant is on mechanical ventilation or a more intensive therapy through Day 28.

Time frame:
Up to Day 28
Reported as:
Median · days
Days on Mechanical Ventilation
daysIbrutinib 420 mg + SOCPlacebo + SOC
Days on Mechanical Ventilation0.0 (0 to 28)0.0 (0 to 28)
Statistical analysis
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Van Elteren's test · p = =0.745 · Difference in medians: 0.0Ibrutinib 420 mg + SOC - Placebo + SOC
SecondaryMedian Duration of Hospitalization

Median duration of hospitalization is defined as the hospitalization discharge date - hospitalization admission date + 1 day. If a participant was hospitalized more than once during the study then the hospitalization time was to be calculated as the sum of all the periods when the participant was hospitalized through Day 28.

Time frame:
Up to Day 28
Reported as:
Median · days
Median Duration of Hospitalization
daysIbrutinib 420 mg + SOCPlacebo + SOC
Median Duration of Hospitalization6.0 (2 to 28)6.5 (3 to 28)
Statistical analysis
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Van Elteren's test] · p = =0.977 · Difference in medians: -0.5Ibrutinib 420 mg + SOC - Placebo + SOC
SecondaryTime to Discharge From Hospital

Time to discharge from hospital is defined as the number of days from Baseline Day 1 to the date of the last evidence that a participant is last discharged from hospital, during the 28 days post baseline. If the specified event did not occur by Day 28, participants were censored. Specifically, a participant without any postbaseline assessment record was to be censored at Baseline Day 1, a participant who died was to have time to discharge from hospital censored at Day 28, a participant who prematurely discontinued from study without a record of hospitalization discharge was to be censored at the earlier timepoint of the date of study discontinuation or Day 28, an on-going participant in the study without a record of hospitalization discharge was to be censored at the earlier timepoint of the date of the last evidence that the participant is hospitalized or Day 28.

Time frame:
Up to Day 28
Reported as:
Median · days
Time to Discharge From Hospital
daysIbrutinib 420 mg + SOCPlacebo + SOC
Time to Discharge From Hospital6.0 (5.0 to 10.0)6.5 (5.0 to 9.0)
Statistical analysis
  • Ibrutinib 420 mg + SOC vs Placebo + SOC · Log Rank · p = =0.969
SecondaryPartial Pressure of Oxygen in Arterial Blood (PaO2) to Fraction of Inspired Oxygen (FiO2) Ratio

The PaO2/FiO2 ratio is the ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2). A PaO2/FiO2 ratio of 300 to 200 is mild, 200 to 100 moderate, and \<100 is severe Adult Respiratory Distress Syndrome (ARDS).

Time frame:
At Study Days 7, 14, 21, and 28
Reported as:
Mean · mmHg
Partial Pressure of Oxygen in Arterial Blood (PaO2) to Fraction of Inspired Oxygen (FiO2) Ratio
mmHgIbrutinib 420 mg + SOCPlacebo + SOC
Day 7100 ± 56.0787 ± 33.35
Day 21269—
SecondaryOxygenation Index

The oxygenation index is used to assess the intensity of ventilatory support required to maintain oxygenation. An index of 0 to \< 25 is predictive of a good outcome; 25 to \<40 indicates a chance of death \>40%; and an index of 40 to 1000 warrants consideration of extracorporeal membrane oxygenation (ECMO).

Time frame:
At Study Days 7, 14, 21, and 28
Reported as:
Mean · units on a scale
Oxygenation Index
units on a scaleIbrutinib 420 mg + SOCPlacebo + SOC
Day 714—
Day 141912
Day 2133 ± 43.6120 ± 1.75
Day 28—12 ± 4.26
SecondaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events (TEAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Time frame:
From first dose of study drug until 30 days following last dose of study drug (up to 70 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsIbrutinib 420 mg + SOCPlacebo + SOC
Number of Participants With Adverse Events1212

Adverse events

Collected over All-cause mortality is reported from enrollment to the end of study; median time on follow-up was Ibrutinib 420 mg + SOC (58.0 days); and Placebo + SOC (62.0 days). Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 30 days after last dose, up to 70 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib 420 mg + SOC1/22 (4.5%)4/22 (18.2%)8/22 (36.4%)
Placebo + SOC1/24 (4.2%)3/24 (12.5%)6/24 (25%)
Most frequent serious events
Most frequent serious events
EventIbrutinib 420 mg + SOCPlacebo + SOC
ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders1/223/24
SEPTIC SHOCKInfections and infestations0/222/24
ACUTE KIDNEY INJURYRenal and urinary disorders0/222/24
PNEUMONIA BACTERIALInfections and infestations1/220/24
SEPSISInfections and infestations1/221/24
STAPHYLOCOCCAL BACTERAEMIAInfections and infestations1/220/24
PULMONARY HAEMORRHAGERespiratory, thoracic and mediastinal disorders1/220/24
PERIPHERAL ARTERY THROMBOSISVascular disorders1/220/24
PNEUMONIAInfections and infestations0/221/24
Most frequent other events
Most frequent other events
EventIbrutinib 420 mg + SOCPlacebo + SOC
ANAEMIABlood and lymphatic system disorders3/222/24
HYPERTENSIONVascular disorders3/221/24
ALANINE AMINOTRANSFERASE INCREASEDInvestigations2/223/24
NAUSEAGastrointestinal disorders2/221/24
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations1/222/24

Baseline characteristics

Full Analysis Set (FAS): all randomized participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)Ibrutinib 420 mg + SOCPlacebo + SOCTotal
Mean50.1 ± 10.5255.2 ± 11.7352.8 ± 11.34
Sex: Female, Male
Sex: Female, Male(Participants)Ibrutinib 420 mg + SOCPlacebo + SOCTotal
Female6814
Male161632
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ibrutinib 420 mg + SOCPlacebo + SOCTotal
White141226
Black or African American448
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander011
Asian011
Multiple000
Other000
Missing4610
COVID-19 symptom onset duration prior to baseline (days)
COVID-19 symptom onset duration prior to baseline (days)(days)Ibrutinib 420 mg + SOCPlacebo + SOCTotal
Mean9.27 ± 2.5679.08 ± 2.7659.17 ± 2.644
Number of participants with a score of 4 on the WHO-8 ordinal scale at screening
Number of participants with a score of 4 on the WHO-8 ordinal scale at screening(Participants)Ibrutinib 420 mg + SOCPlacebo + SOCTotal
Count of participants222446
Stratification factor of prescription for remdesivir
Stratification factor of prescription for remdesivir(Participants)Ibrutinib 420 mg + SOCPlacebo + SOCTotal
Yes131629
No9817
08

Study locations

9 sites
  • Stanford University School of Med /ID# 221954
    Stanford, California 94305-2200, United States
  • Medstar Washington Hospital Center /ID# 221886
    Washington, District of Columbia 20010-3017, United States
  • Duplicate_GW Medical Faculty Associates /ID# 222023
    Washington, District of Columbia 20037, United States
  • Midway Immunology and Research /ID# 222004
    Fort Pierce, Florida 34982, United States
  • University of Miami /ID# 223227
    Miami, Florida 33136, United States
  • Triple O Research Institute /ID# 222944
    West Palm Beach, Florida 33407-3100, United States
  • Brigham & Women's Hospital /ID# 221847
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center /ID# 222994
    Boston, Massachusetts 02215-5400, United States
  • Intermountain Healthcare /ID# 221955
    Salt Lake City, Utah 84103, United States
09

References and documents

Publications

  • Coutre SE, Barnett C, Osiyemi O, Hoda D, Ramgopal M, Fort AC, Qaqish R, Hu Y, Ninomoto J, Alami NN, Styles L, Treon SP. Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study. Open Forum Infect Dis. 2022 Mar 24;9(5):ofac104. doi: 10.1093/ofid/ofac104. eCollection 2022 May. PubMed 35493119 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Requests for access to individual participant data from ibrutinib clinical studies conducted by AbbVie can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu

Data sharing details ↗ · yoda.yale.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in May 2021, 11 months.

Results were first posted in Jun 2022, 1 year after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 11 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2020
First posted
May 5, 2020
StartActual
Jun 6, 2020
Primary completionActual
May 10, 2021
CompletionActual
Jun 8, 2021
Results first posted
Jun 1, 2022
Last update
Jun 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04375397
Lead sponsor
AbbVie
Collaborators
Janssen Research & Development LLC; Pharmacyclics LLC (An AbbVie Company)
Responsible party
Sponsor
First posted
May 5, 2020
Start date
Jun 6, 2020
Primary completion
May 10, 2021
Completion
Jun 8, 2021
Results posted
Jun 1, 2022
Last update
Jun 1, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion